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Abstract
Background: Recent studies suggest HIV-1 inter-subtype differences in co-receptor usage. We examined the
correlation between HIV-1 subtype and co-receptor usage among treatment-naïve HIV-1 subjects in Singapore.
Additionally, we investigated whether the subtype co-receptor association was influenced by stage of infection.
Methods: V3 sequences of HIV-1 envelope protein gp120 were obtained from 110 HIV treatment-naïve patients
and genotypic co-receptor tropism determination was performed using Geno2pheno. Two false-positive rate (FPR)
cut-offs, 10% and 5.75% were selected for tropism testing.
Results: Subtype assignment of viral strains from 110 HIV-infected individuals based on partial sequencing of HIV-1
pol, gp120 and gp41 were as follows: 27 subtype B, 64 CRF01_AE, 10 CRF51_01B, and 9 other subtypes. At FPR=10%,
10 (100%) CRF51_01B-infected subjects and 26 (40.6%) CRF01_AE-infected subjects had CXCR4-using virus,
compared to 7 (25.9%) subtype B subjects and 1 (11.1%) CRF33_01B-infected subject (P < 0.001). At FPR=5.75%, 10
(100%) CRF51_01B-infected subjects and 20 (31.3%) CRF01_AE-infected subjects had CXCR4-using virus, compared
to 4 (14.8%) subtype B and 1 (11.1%) CRF33_01B-infected subjects (P < 0.001). Among those with evidence of
seroconversion within 2 years prior to study enrolment, 100% of CRF51_01B-infected subjects had CXCR4-using
virus, independent of Geno2pheno FPR.
Conclusion: CRF51_01B and CRF01_AE-infected individuals have higher prevalence of CXCR4-usage compared to
subtype B infected individuals. Further studies examining these differences could help optimise the use of CCR5-
antagonist in populations with these subtypes, and increase our understanding of HIV-1 biology.
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Background
HIV-1 infection of immune cells involves the interaction
of the env glycoprotein with CD4 and co-receptors. Co-
receptor usage for viral entry can be divided into CCR5
(R5), CXCR4 (X4) and dual/mixed (DM) virus [1]. DM
virus is able to utilize both the CCR5 and CXCR4-
co-receptors. Infection with CXCR4-using (CXCR4 or
DM) virus precludes therapeutic benefit from CCR5-
antagonist [2]. Additionally, co-receptor switching from
CCR5 to CXCR4-using virus is associated with
increased rates of immunologic decline and late stage
HIV disease [3,4].
Inter-subtype differences in co-receptor usage have
been described in Western and African settings. In a
study of 539 recently diagnosed anti-retroviral naïve
HIV-1 infected individuals in Belgium, CRF01_AE infec-
tion was associated with significantly increased CXCR4-
use compared to subtype B-infection [5]. In another
study of 68 HIV-1 infected, pregnant, antiretroviral naïve
women in Uganda, 9 (36%) of 25 subtype D viruses were
DM tropic, while all the subtype A and A/D-recombin-
ant viruses used CCR5 [6].
In Singapore, subtype B and CRF01_AE are the pre-
dominant HIV-1 circulating strains in a majority ethnic
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Chinese population [7]. In a recent survey, we described
the presence of a novel circulating recombinant form,
CRF51_01B, present in 12.8% of isolates [7,8]. Addition-
ally, we documented the presence of inter-strain
differences in clinical progression between subtype B
and the recombinant strains [9]. This study aimed to de-
termine inter-subtype differences in co-receptor usage in
Singapore. Furthermore, we examined if stage of disease
was a potential confounder in the subtype co-receptor
relationship.
Methods
Details of the study participants and laboratory protocols
have been previously published [7]. From February 2008
to August 2009, this cross-sectional study enrolled 211
treatment-naïve HIV-1 patients presenting for care at
the Singapore Communicable Disease Centre (CDC)
outpatient HIV clinic. Blood from enrolled subjects was
centrifuged to obtain plasma samples, stored at −80°C.
Clinical and demographic information was obtained via
chart review. This study was approved by the National
Healthcare Group ethics committee, and written,
informed consent were obtained from all subjects.
The QIAmp Viral RNA Mini Kit (Qiagen, Valencia, CA,
USA) was used to extract viral RNA from plasma samples.
As previously described, reverse-transcriptase polymerase
chain reaction (RT-PCR), additional nested PCR, sample
purification and Sanger sequencing were used to sequence
portions of the gp120 (HXB2 6904 to 7628) [7]. In brief,
the primers for env C2V5-F1, 50-CTCCAGCTGGTTW
TGCRATT-30 (nt 6880–6899) and C2V5-R1 50-GCCTG
TACCGTCAGCGTTAT-30 (nt 7827–7846) were used
with the following conditions: 50°C for 30 minutes, 95°C
for 15 minutes, 25 cycles at 94°C for 30 seconds, 55°C for
30 seconds, and 72°C for 1.5 minutes. Five microliters of
the first-round PCR product was used in the second-
round reaction in a 50 μL reaction mixture containing 0.8
mM of inter-nested primers C2-V5- F2 (inter) 5#-CAG
CTGGTTWTGCGATTCTAA-3# (nt 6883–6903) and
C2-V5-R2 (inter) 5#-RTYYCCTCCTCCAGGTCT- GA-3
# (nt 7627–7646). Cycling conditions were 94°C for 15
minutes, followed by 35 cycles at 94°C for 30 seconds,
64°C for 30 minutes, and 72°C for 1.5 minutes. The
current analysis was limited to subjects with interpretable
gp120 sequences.
HIV-1 subtypes were assigned using the NCBI geno-
typing database and confirmed with phylogenetic ana-
lysis using reference sequences from the Los Alamos
HIV Sequence Database, based on data from all genomic
regions available. Nucleotide mixtures were considered
when the second highest peak in the electropherogram
was above 25%. V3 sequences harbouring nucleotide
mixtures were translated into all possible amino acid
permutations and subjected to the genotypic prediction
test. Sequences with ≥8 nucleotide mixtures were excluded
because of the high number of amino acid sequences
generated. Genotypic co-receptor prediction was based on
analysis of gp120 sequences using the online Geno2pheno
tool [10]. Based on previous publications, two false-positive
rates (FPR) cutoffs, 5.75% and 10%, were selected for co-
receptor usage interpretation [2,11-13]. Samples below the
FPR cutoff were classified as CXCR4, and those above or
equal to the FPR cutoff were labeled as CCR5-using viruses.
DM tropic viruses were classified as CXCR4-using virus for
our analyses.
As previously described, evidence of recent serocon-
version was defined as presence of a negative HIV test
within 2 years prior to presentation for care [9]. Subject
demographics, transmission risk factor, and median CD4
count at presentation, were analyzed by subtype. Geno-
typic co-receptor usage was analyzed by age, gender, eth-
nicity, transmission risk factor, median CD4 count at
presentation, and subtype. Fisher’s exact test was used to
compare categorical variables, and Wilcoxon rank-sum
test and Median test were used for comparison of
medians. To determine if stage of disease at presentation
was a potential confounder of the relationship of subtype
with co-receptor use, a stratified analysis limited to
subjects with evidence of prior negative HIV test within
2 years before presentation for care was performed.
For every parameter, only samples with complete infor-
mation available were included in the analysis. All statis-
tical analyses were performed using Stata 11 (StataCorp,
College Station, TX, USA).
Results
Of 211 enrolled in the study, 110 (52.1%) subjects had
interpretable gp120 sequences, and were included for
analysis. There were no significant differences in the age,
gender, ethnicity, transmission risk factor or CD4 count
at presentation.
The median age was 36.4 [28.5–45.0] years. Ninety-seven
subjects (88.2%) were males. Eighty-eight (80%) subjects
were ethnic Chinese, 10 (9.1%) subjects were Malays, and
12 (10.9%) of other ethnicity. Fifty (45.6%) reported hetero-
sexual transmission risk, 46 (41.8%) homosexual transmis-
sion, 10 (9.1%) bisexual transmission, and 4 (3.7%)
reporting other risk factors. The median CD4 count at
presentation for care was 303 [128–425] cells/mm3.
Subtype distribution was as follows: 27 (24.6%) sub-
type B, 64 (58.2%) CRF01_AE, 10 (9.1%) CRF51_01B,
and 9 (8.2%) other subtypes (2 CRF_02AG, 1 CRF07_BC,
2 CRF15_01B, 3 CRF33_01B, and 1 CRF34_01B). There
was no statistically significant difference between
subtypes, with regards to median age, gender, ethnicity
or CD4 count at presentation for care (Table 1). A
higher proportion of subtype B and CRF51_01B-infected
subjects (51.9% and 50.0% respectively) reported
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homosexual transmission risk, compared to CRF01_AE-
infected subjects and those with other subtypes (37.5%
and 33.3% respectively) (P = 0.003).
There was no statistically significant difference in me-
dian age, gender, ethnicity or transmission risk between
subjects infected with CXCR4-using or CCR5-using
virus (Table 2). Using a higher FPR=10%, subjects with
CXCR4-using virus had a lower CD4 count at presenta-
tion for care (226 [32–402] cells/mm3) compared to
subjects infected with CCR5-using virus (333 [200 to
462] cells/mm3) (P = 0.013). At a lower FPR of 5.75%,
this association remained, with a median CD4 count of
219 (35–336) cells/mm3 in the CXCR4 population, and a
median CD4 count of 333 [189–470] cells/mm3 in the
CCR5 population. Among the same subtype, all 10
(100%) CRF51_01B-infected subjects and 26 out of 64
(40.6%) CRF01_AE-infected subjects had CXCR4-using
virus, compared to 7 out of 27 (25.9%) subtype B and 1
out of 9 (11.1%) CRF33_01B-infected subjects at
FPR=10% (P < 0.001). The association of subtype and
co-receptor use remained significant when the FPR was
changed to 5.75%. At FPR=5.75%, all 10 (100%)
CRF51_01B-infected subjects and 20 out of 64 (31.3%)
CRF01_AE-infected subjects had CXCR4-using virus,
compared to 4 out of 27 (14.8%) subtype B and 1 out of
9 (11.1%) CRF33_01B-infected subjects (P < 0.001).
To examine the influence of stage of disease, an ana-
lysis limited to individuals with evidence of recent sero-
conversion (n=25) was performed. Nine (36.0%) of 25
recently-infected individuals had CXCR4-using virus,
compared to 26 (30.6%) of 85 individuals without evi-
dence of recent infection (P = 0.631). Excluding the 10
CRF51_01B-infected individuals from analysis, 4 (20.0%)
of 20 recently-infected individuals had CXCR4-using
virus compared to 21 (26.3%) of 80 individuals without
evidence of recent infection (P = 0.774). At FPR=5.75%,
all CRF51_01B and 3 out of 13 (23.1%) CRF01_AE-
infected subjects had CXCR4-using virus compared to 1
out of 6 (16.7%) of the subtype B and none from the
CRF33_01B-infected subjects (P = 0.001). At FPR=10%,
all CRF51_01B-infected subjects had CXCR4-using virus
compared to 0 to 33% of the other subtypes with
CXCR4-usage (P = 0.011). We repeated the analysis,
limiting the subjects to those meeting the definition of
recent seroconversion as a maximum interval of 1 year
between the last negative HIV-1 test and first positive
HIV-1 test. The inferences remained unchanged with a
significantly higher proportion of CRF51_01B-infected
subjects having CXCR4-using virus (data not shown).
Discussion
Our study found that CRF51_01B and CRF01_AE HIV-1
virus had higher prevalence of CXCR4-usage compared
to subtype B. Interestingly, all CRF51_01B isolates, in-
cluding those from subjects with evidence of recent
seroconversion, were CXCR4-using. Limiting the ana-
lysis to subjects with evidence of recent seroconversion,
the difference in proportion of CXCR4-using virus
among subtype B and CRF01_AE-infected subjects was
less apparent, possibly due to smaller numbers of
subjects.
The high prevalence of CXCR4-use among CRF01_AE-
infected subjects could be a factor in the increased rates of
CD4 T-cell decline previously observed among CRF01_AE
compared to subtype B-infected subjects [9]. The high
prevalence of CXCR4-use among CRF51_01B-infected
subjects suggests that CRF51_01B-infected patients could
experience faster immunologic decline compared to
subtype B-infected patients; a hypothesis supported by pre-
liminary analyses documenting higher proportion of AIDS
at presentation, and greater rate of CD4 T-cell decline
among CRF51_01B-infected subjects compared to subjects
Table 1 Baseline demographics and CD4 cell count, by subtype
Patient characteristics Subtype B
(n=27), n (row %)
CRF01_AE
(n=64), n (row %)
CRF51_01B
(n=10), n (row %)
Others
(n=9), n (row %) P-value
Median age (median, IQR) 28.9 [6.6–38.1] 37.2 [29.1–46.4] 39.8 [29.9–41.2] 36.7 [36.3–49.3] 0.092
Male gender 25 (92.6) 55 (85.9) 9 (90.0) 8 (88.9) 0.919
Ethnicity
Chinese 18 (66.7) 54 (84.4) 9 (90.0) 7 (77.8) 0.227
Non-Chinese 9 (33.3) 10 (15.6) 1 (10.0) 2 (22.2)
Transmission risk
Heterosexual 8 (29.6) 37 (57.8) 1 (10.0) 4 (44.4) 0.003
MSM 14 (51.9) 24 (37.5) 5 (50.0) 3 (33.3)
Others 5 (18.5) 3 (4.7) 4 (40.0) 2 (22.2)
CD4 count at presentation (median, IQR) 416 [275–493] 263 [52–401] 167 [35–338] 248 [219–304] 0.092
Abbreviations: IQR, interquartile range; MSM, men who have sex with men.
a Blood transfusion, intravenous drug use (IVDU), bisexual.
b Other subtypes: CRF02_AG, CRF34_01B, CRF07_BC, CRF33_01B, CRF15_01B.
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infected with subtype B [14]. The virion of CRF51_01B
comprises a recombinant structure of CRF01_AE and sub-
type B [7,8]. Specifically, portions of CRF51_01B harbour
CRF01_AE in the gp120 and subtype B in the protease and
gp41 regions. Given the unique patterns in inter-strain re-
combination, future comparative analysis on the viral gen-
etic elements could potentially lead to the identification of
key determinants that account for the distinct biological
phenotype (including tropism and co-receptor usage)
implicated in this study.
For clinical practice, our current findings highlight the
need for co-receptor determination prior to prescribing
CCR5-antagonist to individuals infected with CRF01_AE
or CRF51_01B [2]. As noted in a recent meta-analysis
and consensus statement on the clinical management of
HIV-1 tropism testing, genotypic analysis of the HIV
third hypervariable loop (V3) is the most practical mo-
dality of testing. The laboratory turnaround time for
phenotypic testing precludes widespread clinical use of
this method. In the above noted meta-analysis and con-
sensus statement, the Geno2pheno interpretation system
was recommended as the best-validated interpretation
algorithm, while acknowledging the dearth of data in
non-B subtypes. Accordingly, there is need for better
data and potentially improved algorithms tailored for
non-B HIV-1 subtypes.
V3-based genotyping algorithms are generally less sen-
sitive in identifying X4 variants for non-B subtypes
because they were built using datasets of genotype-
phenotype correlations from subtype B viruses [15-17].
According to a study evaluating the reliability of several
V3-based genotypic predictors, the sensitivity to identify
X4 variants was 90% for B subtypes and 61% for non-B
subtypes using Geno2pheno compared with the pheno-
typic assay [15]. Seclen et al. determined a sensitivity of
58% and specificity of 79% for non-B subtypes,
compared with a sensitivity of 94% and specificity of
51% for subtype B, using the Geno2pheno tool [17]. The
inadequacy of current genotypic tools for predicting
CXCR4-using viruses among non-B subtypes thus
underscores the need to improve the information on the
correlation between phenotypic and genotypic methods
for viral tropism determination in patients infected with
non-B HIV-1.
Some limitations of this study and the use of genotypic
co-receptor prediction assay should be acknowledged.
Due to the genetic variations in the diverse sample
population, it was technically challenging to optimize
the cycling conditions that could be universally applied
for the DNA cycle sequencing of all HIV subtypes. This
has likely resulted in the lower proportion (51%) of in-
terpretable gp120 sequences reported in the study
herein. Secondly, our study lacks phenotypic confirm-
ation of co-receptor status. Genotypic co-receptor deter-
mination is best validated for subtypes B and C, and
little data exists specifically on its utility for CRF01_AE
Table 2 Demographics and clinical characteristics, by co-receptor tropism
FPR Criteria FPR = 10 FPR = 5.75
Patient characteristics CXCR4(n=44), n (row %)
R5
(n=66), n (row %) P-value
CXCR4
(n=35), n (row %)
R5
(n=75), n (row %) P-value
Median age (median, IQR) 36.9 [28.8–45.4] 36.4 [27.6–44.6] 0.665 39.7 [29.4–45.4] 35.6 [27.6–45.0] 0.539
Male gender 38 (39.1) 59 (61.0) 0.765 30 (30.9) 67 (69.1) 0.752
Ethnicity
Chinese 34 (77.3) 54 (81.8) 0.630 27 (77.1) 61 (81.3) 0.617
Non-Chinese 10 (22.7) 12 (18.2) 8 (22.9) 14 (18.7)
Transmission risk
Heterosexual 20 (45.5) 30 (45.5) 0.945 15 (42.9) 36 (48.0) 0.502
MSM 23 (52.3) 33 (50.0) 14 (40.0) 32 (42.7)
Othersa 1 (3.0) 3 (4.5) 6 (17.1) 7 (9.3)
CD4 count at presentation (median, IQR) 226 [32–402] 333 [200–462] 0.013 219 [35–336] 333 [189–470] 0.025
Evidence of recent seroconversion (n=25)
Subtype B 2 (8.0) 4 (16.0) 0.011 1 (4.0) 5 (20.0) 0.007
CRF01_AE 3 (12.0) 10 (40.0) 3 (12.0) 10 (40.0)
CRF51_01B 5 (2.0) 0 (0.0) 5 (20.0) 0 (0.0)
Othersc 0 (0.0) 1 (4.0) 0 (0.0) 1 (4.0)
Abbreviations: IQR, interquartile range; MSM, men who have sex with men; FPR, false-positive rate.
a Blood transfusion, intravenous drug use (IVDU), bisexual.
b Other subtypes: CRF02_AG, CRF34_01B, CRF07_BC, CRF15_01B.
c Other subtypes: CRF33_01B.
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isolates [2]. A prior study with a cohort of 103 patients
harbouring various subtypes demonstrated a good cor-
relation of 88% sensitivity and 87% specificity against
phenotypic assessment of HIV-1 co-receptor usage [18].
Another study examining the accuracy of Geno2pheno
prediction at 10% FPR among 23 subtype B and 79 non-
B isolates demonstrated a 97% sensitivity, 93% specifi-
city, compared to phenotypic co-receptor determination
[19]. However, poor genotype-phenotype correlations
have also been reported in some studies, especially for
the detection of X4 variants. Retrospective analysis of a
cohort of treatment-experienced patients enrolled in the
framework of two phase III clinical trials MOTIVATE 1
and 2 showed that sensitivity of Geno2pheno to detect
X4 variants was 63% compared with the Trofile™ pheno-
typic assay, even though the genotypic test was able to
distinguish between responders and non-responders to
maraviroc [11].
Conclusion
In conclusion, the study herein showed that HIV-1 sub-
type CRF51_01B and CRF01_AE-infected subjects have
higher prevalence of CXCR4-usage compared to subtype
B. Larger studies involving phenotypic co-receptor deter-
mination would strengthen these findings. Further stud-
ies examining the clinical implications of these findings
would help optimise the usage of CCR5-antagonists in
treatment, and further our understanding of HIV
biology.
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